亚太急性冠状动脉综合征市场 – 行业趋势和 2029 年预测

亚太急性冠状动脉综合征市场分析与洞察

预计亚太地区急性冠状动脉综合征市场将在 2022 年至 2029 年的预测期内实现显着增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 6.1%，预计到 2029 年将达到 33.0422 亿美元。推动急性冠状动脉综合征市场增长的主要因素是冠状动脉疾病、缺血性心脏病和血管疾病等慢性疾病患病率的上升、老年人口的增长、市场参与者提供的广泛产品，引领急性冠状动脉综合征市场在未来增长。

急性冠状动脉综合征是指心脏血流量减少的一组疾病。与 ACS 相关的疾病包括 ST 段抬高型心肌梗死 (STEMI)、非 ST 段抬高型心肌梗死 (NSTEMI) 和不稳定型心绞痛。它是一种冠心病 (CHD)，占 35 岁以上人群死亡总数的三分之一。某些形式的 CHD 可能没有症状，但 ACS 始终有症状。

急性冠状动脉综合征（ACS）是冠心病（CHD）的一种表现，通常是由于冠状动脉中的斑块破裂（动脉粥样硬化）所致。该病的常见危险因素包括吸烟、高血压、糖尿病、高脂血症、缺乏运动、家庭肥胖和营养不良。可卡因滥用也会导致血管痉挛。早期心肌梗塞家族史（55 岁）也是高危因素。

亚太急性冠状动脉综合征市场报告提供了市场份额、新发展、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预​​期目标。

Acute Coronary Syndrome Market Dynamics

Drivers

• Rise in Prevalence of Chronic Diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases

As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the U.S., Europe, and Asia Pacific region. This signifies that the increase in research and development investment for the discovery and development of treatments of acute coronary syndrome boosts the market growth.

• Growing Geriatric Population

The number of elderly people reporting respective cardiovascular diseases is high. Owing to this, it is anticipated that the ever-increasing geriatric population, which is expected to rise in future years worldwide mainly in Middle East and Africa& Asia-Pacific region, creates an opportunity for market growth in the forecast period.

• Wide Range of Products Offered by Market Players

Strategic product launches and collaborations done by major companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions. This strategy is allowing the companies to strengthen their footprints in the market. Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the market.

Opportunities

• Surge in Technological Advancements for Cardiovascular Disease

As technology advances rapidly, it improves how one manages cardiovascular diseases. In addition, recent healthcare monitoring applications and gadgets have enhanced the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the global acute coronary syndrome market in the forecast period.

Also, governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.

Restraints/Challenges

Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are the restrains and challenges for the growth of acute coronary syndrome market.

The increased intricacy and cost of the cardiology devices and robust investments would increase the costs. The increased cost would result in delayed treatment of the patients in hospitals and clinics and clearance of these product is very rigorous and time-consuming many of the products find it difficult to get approved due to not complying with the regulations which may hamper the market growth.

This acute coronary syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on acute coronary syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In November 2021, Merck, announced the successful completion of the acquisition of Acceleron Pharma Inc. It is an important and strategic opportunity for company to continue growing their cardiovascular portfolio and pipeline that builds on long and proud legacy in cardiovascular disease and further bolsters company’s business development strategy fueled by Acceleron’s groundbreaking research.

Asia-Pacific Acute Coronary Syndrome Market Scope

Asia-Pacific acute coronary syndrome market is categorized based on type, diagnosis, treatment and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

• Non-St-Elevation Myocardial Infarction
• St-Elevation Myocardial Infarction
• Unstable Angina

On the basis of type, the Asia-Pacific acute coronary syndrome market is segmented into non-St-elevation myocardial infarction, St-elevation myocardial infarction and unstable angina.

Diagnosis

• Stress Test
• Blood Tests
• Imaging
• Others

On the basis of diagnosis, the Asia-Pacific acute coronary syndrome market is segmented into stress test, blood test, imagining and others.

Treatment

• Medication
• Surgery

根据治疗方法，亚太急性冠状动脉综合征市场分为药物治疗和手术治疗。

最终用户

• 医院和诊所
• 诊断中心
• 学术机构
• 其他的

根据最终用户，亚太急性冠状动脉综合征市场分为医院和诊所、诊断中心、学术机构和其他。

急性冠状动脉综合征市场区域分析/见解

亚太急性冠状动脉综合征市场进一步细分为中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾和亚太其他地区等主要国家。

亚太地区的中国在市场份额和市场收入方面占据急性冠状动脉市场的主导地位，并将在预测期内继续保持主导地位。这是由于该国医疗基础设施发达且患者人数不断增加。

报告的国家部分还提供了影响单个市场因素和市场法规变化的信息，这些因素和变化会影响市场的当前和未来趋势。新车和替换车销售、国家人口统计数据和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了亚太地区品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。

竞争格局和亚太急性冠状动脉综合征市场份额分析

亚太急性冠状动脉综合征市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对亚太急性冠状动脉综合征市场的关注有关。

亚太急性冠状动脉综合征市场的一些主要知名参与者包括 Movianto (美国)、Sharp (美国)、Thermo Fisher Scientific Inc.,(美国)、Catalent, Inc (美国)、PCI Pharma Services (美国)、Almac Group (英国)、PAREXEL International Corporation (美国)、Bionical Ltd. (英国)、Alium Medical Limited (英国)、MYODERM (英国)、Clinigen Group plc (英国)、Ancillare, LP (美国)、SIRO Clinpharm (印度)、CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (美国)、Biocair (英国) 等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-68013